BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37417768)

  • 1. Sulfhydryl compound levels are associated with ATO-induced side effects in acute promyelocytic leukemia patients.
    Sui M; Wei H; Shen X; Gao K; Zhang Z; Zhang Q
    Hematology; 2023 Dec; 28(1):2231738. PubMed ID: 37417768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Indicators of Hepatotoxicity in Newly Diagnosed Acute Promyelocytic Leukemia Patients Undergoing Arsenic Trioxide Treatment.
    Zhang Z; Zhang S; Zhang F; Zhang Q; Wei H; Xiu R; Zhao Y; Sui M
    Biol Trace Elem Res; 2024 Jan; 202(1):122-132. PubMed ID: 37097388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The kinetics of white blood cell and the predictive factors of leukocytosis under oral or intravenous arsenic as the first-line treatment for acute promyelocytic leukemia.
    Wang F; Jia JS; Wang J; Zhao T; Jiang Q; Jiang H; Zhu HH
    Leuk Res; 2017 Oct; 61():84-88. PubMed ID: 28934679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of gamma-glutamyltransferase in acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
    Sui M; Wei H; Zhang Q; Xiu R; Shen X; Zhang Z; Zhou J
    Hematology; 2021 Dec; 26(1):58-64. PubMed ID: 33402059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute kidney injury in acute promyelocytic leukemia: a possible adverse effect of high dose arsenic trioxide in obese patients.
    Jen WY; Sasaki K; Rausch CR; DiNardo CD; Kadia TM; Yilmaz M; Borthakur G; Alvarado Y; McCue D; McCue D; Kantarjian HM; Ravandi F
    Leuk Lymphoma; 2024 Mar; 65(3):378-382. PubMed ID: 38054837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
    Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
    Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arsenic trioxide dose capping to decrease toxicity in the treatment of acute promyelocytic leukemia.
    Zacholski K; Hambley B; Hickey E; Kashanian S; Li A; Baer MR; Duong VH; Newman MJ; DeZern A; Gojo I; Smith BD; Levis MJ; Varadhan R; Gehrie E; Emadi A; Ghiaur G
    J Oncol Pharm Pract; 2022 Sep; 28(6):1340-1349. PubMed ID: 34134554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Herpes zoster during arsenic trioxide therapy for acute promyelocytic leukemia.
    Freyer CW; Peterson CE; Man Y; Przespolewski A; Baron J; Luger SM
    Leuk Lymphoma; 2021 Mar; 62(3):696-702. PubMed ID: 33106056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide.
    Camacho LH; Soignet SL; Chanel S; Ho R; Heller G; Scheinberg DA; Ellison R; Warrell RP
    J Clin Oncol; 2000 Jul; 18(13):2620-5. PubMed ID: 10893295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the efficacy and safety of arsenic trioxide dosing in obese patients with acute promyelocytic leukemia.
    Barsoum B; Henneman A; Ahmad S; Ghiuzeli C
    Leuk Lymphoma; 2021 Mar; 62(3):703-708. PubMed ID: 33107373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia.
    Zhou J; Zhang Y; Li J; Li X; Hou J; Zhao Y; Liu X; Han X; Hu L; Wang S; Zhao Y; Zhang Y; Fan S; Lv C; Li L; Zhu L
    Blood; 2010 Mar; 115(9):1697-702. PubMed ID: 20029047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leukocytosis and retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide.
    Jin B; Hou KZ; Liu YP; Yu P
    Chin Med Sci J; 2006 Sep; 21(3):171-4. PubMed ID: 17086739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia.
    Soignet SL; Frankel SR; Douer D; Tallman MS; Kantarjian H; Calleja E; Stone RM; Kalaycio M; Scheinberg DA; Steinherz P; Sievers EL; Coutré S; Dahlberg S; Ellison R; Warrell RP
    J Clin Oncol; 2001 Sep; 19(18):3852-60. PubMed ID: 11559723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021.
    Gill H; Raghupathy R; Lee CYY; Yung Y; Chu HT; Ni MY; Xiao X; Flores FP; Yim R; Lee P; Chin L; Li VWK; Au L; Au WY; Ma ESK; Mohan D; Kumana CR; Kwong YL
    BMC Cancer; 2023 Feb; 23(1):141. PubMed ID: 36765318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Coagulopathy and differentiation syndrome: the main complications of the initial treatment of acute promyelocytic leukemia].
    Korístek Z; Zák P
    Vnitr Lek; 2008; 54(7-8):745-50. PubMed ID: 18780573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Relationship between the Therapeutic Dose of Arsenic Trioxide and Relapse in Acute Promyelocytic Leukemia].
    Wang HY; Zhang HY; Liu Y; Zhang XX; Gong S; Chen LM; Wang MC; Xi JY; Liu X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):705-709. PubMed ID: 29950207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial).
    Wang HY; Gong S; Li GH; Yao YZ; Zheng YS; Lu XH; Wei SH; Qin WW; Liu HB; Wang MC; Xi JY; Chen LM; Zhang M; Zhang XX; Zhang HY; Zhang CS; Wald DN; Zhu HH; Liu L; He PC
    Blood Cancer J; 2022 Nov; 12(11):158. PubMed ID: 36404343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective study of arsenic trioxide for childhood acute promyelocytic leukemia in China: a single-center experience.
    Wang H; Hao L; Wang X; Li J; Wu Q; Bian S
    Int J Hematol; 2010 Jun; 91(5):820-5. PubMed ID: 20461563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiation syndrome and coagulation disorder - comparison between treatment with oral and intravenous arsenics in pediatric acute promyelocytic leukemia.
    Luo JS; Zhang XL; Huang DP; Chen YQ; Wan WQ; Mai HR; Chen HQ; Wen H; Liu RY; Chen GH; Li Y; Luo XQ; Tang YL; Huang LB
    Ann Hematol; 2023 Jul; 102(7):1713-1721. PubMed ID: 37199788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The comparison of plasma arsenic concentration and urinary arsenic excretion during treatment with Realgar-Indigo naturalis formula and arsenic trioxide in children with acute promyelocytic leukemia.
    Liao LH; Chen YQ; Huang DP; Wang LN; Ye ZL; Yang LH; Mai HR; Li Y; Liang C; Luo JS; Wang LN; Luo XQ; Tang YL; Zhang XL; Huang LB
    Cancer Chemother Pharmacol; 2022 Jul; 90(1):45-52. PubMed ID: 35760920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.